Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.45 |
| ▸ | LSS | P48449 | 1/20 | 0.43 |
| ▸ | SORD | Q00796 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 4/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31182225 | 0.82 | HRH4 (0.43) | HRH3LSSHRH4MAP4K4 | |
| SCHEMBL22932938 | 0.82 | OGA (0.52) | HRH3LSSSORDHRH4CYP17A1 | |
| SCHEMBL16684774 | 0.81 | HRH3 (0.69) | HRH3LSSSORDHRH4CYP17A1 | |
| Hydrochloric Acid SCHEMBL16684891 | 0.79 | HRH3 (0.67) | HRH3LSSSORDHRH4CYP17A1 | |
| Hydrochloric Acid SCHEMBL2272733 | 0.79 | HRH3 (0.67) | HRH3LSSSORDHRH4CYP17A1 | |
| SCHEMBL785843 | 0.78 | HRH4 (0.57) | HRH3LSSHRH4 | |
| SCHEMBL24799135 | 0.78 | SORD (0.48) | HRH3LSSSORDHRH4 | |
| SCHEMBL3167113 | 0.78 | CXCR4 (0.49) | HRH3SORDHRH4 | |
| SCHEMBL7660332 | 0.77 | LSS (0.45) | HRH3LSSSORDHRH4CYP17A1 | |
| SCHEMBL16691295 | 0.77 | HRH4 (0.46) | HRH3LSSSORDHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969405-B2 | Anticancer compounds and methods of making and using same | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2015-03-03 | — | — | US | disclosed |
| US-20110178098-A1 | ANTICANCER COMPOUNDS AND METHODS OF MAKING AND USING SAME | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178098-A1 | ANTICANCER COMPOUNDS AND METHODS OF MAKING AND USING SAME | MKI67, MCL1, BAD | HRH3 4503/4885LSS 58/4885SORD 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.